The Chiron Diagnostics ACS:180 Tobramycin Assay is for the quantitative determination of tobramycin in serum or plasma using the Chiron ACS:180 Automated Chemiluminescence Systems. Monitoring the patient's serum or plasma tobramycin levels is important both to ensure that the drug is present in therapeutic concentrations and to avoid toxicity.

Device Description

The Chiron Diagnostics ACS:180 Tobramycin assay is a competitive immunoassay using direct, chemilumenescent technology. Tobramycin in the patient sample competes with acradinium ester-labeled tobramycin in the Lite Reagent for a limited amount of monoclonal mouse anti-tobramycin antibody, which is covalently coupled to the paramagnetic particles in the Solid Phase. An inverse relationship exists between the amount of tobramycin present in the patient sample and the amount of relative light units (RLUs) detected by the ACS:180® system.

AI/ML Overview

Here's a summary of the acceptance criteria and study details for the Chiron Diagnostics ACS:180 Tobramycin Assay, based on the provided text:

Acceptance Criteria and Device Performance

Acceptance Criteria Category	Acceptance Criteria	Reported Device Performance
Sensitivity (Detection Limit)	Not explicitly stated, but implies detection of therapeutic concentrations	Minimum detectable concentration of 0.18 µg/mL
Measurement Range	Not explicitly stated, but implies coverage of therapeutic concentrations	Measures tobramycin concentration up to 13 µg/mL
Accuracy (Agreement with Predicate)	Not explicitly stated, but implied high correlation with an alternate method	Correlation coefficient (r) = 0.99 for 293 samples in the range of 0.22 to 9.03 µg/mL. Equation: ACS:180 Tobramycin = 0.903 (alternate method) + 0.10 µg/mL

Study Details

Sample size used for the test set and the data provenance:
- Sample Size: 293 samples.
- Data Provenance: Not specified (e.g., country of origin, retrospective or prospective).
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not applicable/Not provided. The "ground truth" for the accuracy study was an "alternate fluorescence polarization (FPIA) method," which is a laboratory method, not expert-based.
Adjudication method for the test set:
- Not applicable. The comparison was against a laboratory method.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No. This device is an automated immunoassay for drug level measurement, not an AI-assisted diagnostic imaging or interpretation tool involving human readers.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Yes. The performance described for the ACS:180 Tobramycin assay is its standalone, automated performance.
The type of ground truth used:
- Alternative Method Comparison: The accuracy of the ACS:180 Tobramycin assay was assessed by comparing its results against an "alternate fluorescence polarization (FPIA) method." This constitutes a comparative method study, where the FPIA method serves as the reference or "ground truth."
The sample size for the training set:
- Not provided. The document describes performance data, but does not detail the development or training of the assay (which, in this context, refers to the development of the immunoassay reagents and calibration, not an AI model).
How the ground truth for the training set was established:
- Not provided. As this is not an AI/machine learning model in the conventional sense, the concept of a "training set" and its "ground truth establishment" as typically applied to AI does not directly apply in the same way. The development of an immunoassay involves optimizing reagent concentrations, antibody specificity, and calibration using known standards, but these details are not in the provided summary.

Summary

{0}------------------------------------------------

CHIRON LEGAL

K974029

I. Following is the revised Summary of Safety and Effectiveness:

Summary of Safety and Effectiveness

FE: ? ""

As required by 21 CFR 807.92, the following 510(k) Summary is provided:

1. Submitter Information

FEB 1 2 1998

Contact person:

Thomas F. Flynn

September 11, 1997

Address: 63 North Street Medfleld, MA 02052

Phone: FAX: e-mail:

(508) 359-3877

Chiron Diagnostics Corporation

(508) 359-3885 thomas.flynn@chirondiag.com

Date Summary Prepared:

2. Device Information

Proprietary Name: Common Name: Classification Name: ACS Tobramycin Tobramycin Immunoassay Class II Tobramycin Test System, 21 CFR 862.3900

3. Predicate Device Information

Name:	TDX/FLx Tobramycin Immunoassay
Manufacturer:	Abbott Laboratories
510(k) Number:	Not Known

4. Device Description

{1}------------------------------------------------

5. Statement of Intended Use

For the quantitative determination of tobramycin in serum or plasma using the Chiron Diagnostics ACS:180® Automated Chemiluminescence Systems.

6. Summary of Technological Characteristics

The Chiron Dlagnostics ACS Tobramycin assay is a competitive chemiluminescent immunoassay.

7. Performance Data

Sensitivity

The ACS Tobramycin immunoassay measures tobramycin concentration up to 13 ug/mL with a minimum detectable concentration of 0.18 µg/mL.

Accuracy

For 293 samples in the range of 0.22 to 9.03 ug/mL, the correlation between the ACS:180 Tobramycin and an atternate fluorescence polarization (FPIA) method is described by the equation:

ACS:180 Tobramycin = 0.903 (alternate method) + 0.10 µg/mL

Correlation coefficient (r) = 0.99

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three stripes forming its wing and body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular fashion around the eagle.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Thomas F. Flynn Manager, Regulatory Affairs & Compliance CHIRON DIAGNOSTICS CORPORATION 63 North Street Medfield, MA 02052

FEB 1 2 1998

Re: K974029 Trade Name: ACS Tobramycin Regulatory Class: II Product Code: LCR 91 Dated: December 23, 1997 Received: December 24, 1997

Dear Mr. Flynn:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the ___ . Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.

This letter will allow you to begin marketing your device as described " in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Company Confidential

Page _ of _

510(k) Number (if known): K974029

Device Name: Chiron Diagnostics ACS:180 Tobramycin Assay

Indications for Use: -----------------------

Andhut In AWM

(Division Sign-Off)
Division of Clinical Laboratory Devices 19974029

(PLEASE DO NOT WRITE BELOW THIS LINE--- CONTINUE ON ANOTHER PAGE, IFF. -----NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

510(k) Number

Over-The-Counter Use (Optional Format 1-2-96)

ACS:180 Tobramycin 510(k)

22 October, 1997

Regulation Number and Section

§ 862.3900 Tobramycin test system.

(a)
Identification. A tobramycin test system is a device intended to measure tobramycin, an aminoglycoside antibiotic drug, in plasma and serum. Measurements obtained by this device are used in the diagnosis and treatment of tobramycin overdose and in monitoring levels of tobramycin to ensure appropriate therapy.(b)
Classification. Class II.